WindyMarieDean-ColombMD

Oncology • Newnan, GA

Physician

Join to view full profile

Dr. Dean-Colomb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dean-Colomb's full profile

Already have an account?

Office
775 Poplar Rd
Ste 130
Newnan, GA 30265
Phone+1 770-400-4720

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Carle Foundation HospitalResidency, Internal Medicine, 2001 - 2005
University of Illinois College of MedicineClass of 2001

Certifications & Licensure

MS State Medical License 2018 - 2025
GA State Medical License 2021 - 2024
LA State Medical License 2005 - 2024
AL State Medical License 2011 - 2023
KS State Medical License 2020 - 2021
SD State Medical License Active through 2021
WY State Medical License 2020 - 2021
TX State Medical License 2007 - 2012
IL State Medical License 2001 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
Completed
Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

42 citations
Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers
Ritu Arora, David C. Schmitt, Balasubramanyam Karanam, Ming Tan, Clayton Yates
Oncotarget. 2015-01-08
59 citations
Sulindac inhibits tumor cell invasion by suppressing NF-κB mediated transcription of microRNAs
Xiaobo Li, Lin Gao, Q Cui, Bernard D. Gary, Donna Lynn Dyess
Oncogene. 2012-11-29
19 citations
Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer.
Anusha Angajala, Essynce Mothershed, Melissa Davis, Shweta Tripathi, Qinghua He
Translational Oncology. 2019-03-01